CHM-971

CHM-971 is an investigational small molecule drug candidate discovered and developed by Chemia, a biotechnology company that utilizes a proprietary artificial intelligence platform to identify and optimize natural product-inspired therapeutics. The candidate was identified through Chemia's platform which focuses on addressing challenging biological targets that are often considered 'undruggable' by traditional methods. While specific details regarding its molecular target and primary therapeutic indication have not been publicly disclosed, CHM-971 is part of an internal pipeline that generally targets high-value pathways in oncology and inflammatory diseases. As of early 2024, the program is in the early stages of development, progressing through optimization and IND-enabling studies.